Overcoming cancer drug resistance

Pipeline

Cancer drug resistance

INVESTORS

Interim Report Q1 2022

Interim Report Q1 2022

President & CEO Bo Rode Hansen reflects on our achievements and outlook for 2022

PRESS RELEASES

Scandion Oncology announces change to its Board of Directors

Thomas Feldthus will step down from the Board of Directors.

Scandion Oncology – Interim Report Q1 2022

Scandion Oncology (Scandion) today announces its interim report for Q1 2022. The following is taken from the report.

Invitation to Scandion Oncology webcast and conference call May 19, 2022

Scandion Oncology (Scandion) will publish its Q1 2022 interim report on Thursday, May 19, 2022 before 09:00 CET. Scandion Oncology’s Executive Management will host a webcast and conference call the same day at 10:00 CET presenting the results and a company update. At the end of the presentation there will be a Q&A session. Access to the event c …

View all press releases

UPCOMING EVENTS

Økonomisk Ugebrev Life science investor konference

Meet Scandion Oncology at Økonomisk Ugebrev Life Science Investor Konference

Redeye Growth Day 2022

Meet Scandion Oncology at Redeye Growth Day 2022

BIO International Convention 2022

Meet Scandion Oncology at BIO International Convention 2022

View all upcoming events

Learn more about our unique first-in-class lead compound SCO-101

Read more about SCO-101

LATEST PRESENTATIONS

Redeye interview (video)

Watch the ”get to know-interview” with President & CEO Bo Rode Hansen from April 11, 2022.

Aktieinfo Investor Conference

Watch Bo Rode Hansen’s presentation from Aktieinfo on April 4, 2022

26 January 2022

Edison Open House: Global Healthcare 2022

Watch the interview with President & CEO, Bo Rode Hansen released on January 26, 2022

View all presentations

INVESTOR

Scandion Oncology Capital Markets Day

September 8, 2021

Watch the presentations from Scandion Oncology’s Capital Markets Day

Capital Markets Day View all presentations

CAREER

A great place to work

For talented, ambitious individuals who share our passion for science and drug development, we offer an exciting work environment, along with the opportunity to make a difference for the many cancer patients in need for novel treatments